Is Cellular Reprogramming Junk Science? Nearly 20 Patients Are Getting Eye Injections in the First FDA-Cleared Cellular Trial
Boston‑based Life Biosciences has begun the first FDA‑cleared human trial of cellular reprogramming, delivering an epigenetic injection into the eye of a glaucoma patient. The approach aims to reset the epigenetic age of ocular cells, potentially reversing age‑related damage. Co‑founder David Sinclair, a prominent yet controversial longevity researcher, provided the scientific foundation though he is not involved in day‑to‑day operations. Researchers will monitor safety and efficacy over six months, making this a pivotal test for anti‑aging therapeutics.
Can't Exercise? Sulforaphane From Broccoli Sprouts Reverses Frailty in Aging Mice
A recent Science Advances study showed that sulforaphane, a compound from broccoli sprouts, can reverse frailty phenotypes in aging mice when administered intraperitoneally at 2 mg/kg three times a week. Translating that exposure to humans yields an estimated systemic dose of...
Walk This Meal: AI Predicts Which Dinners Are Worth the Post-Meal Stroll
A Weizmann Institute team analyzed 55,954 free‑living meals from 1,627 non‑diabetic adults, linking phone‑logged meals, continuous glucose monitor data, and wearable step counts. They found that post‑meal walking of roughly 500 steps or more within two hours blunted glucose excursions,...
Just Three Hours of Weekly Exercise Combining Cardio, Strength Training, and Stretching May Help You Live Longer, Study Finds
A secondary analysis of the U.S. POINTER trial found that older adults who followed a structured regimen of cardio, resistance, and flexibility training—totaling three to three‑and‑a‑half hours per week—experienced a measurable reduction in frailty index and better cognitive function over...
Ultra-Precise Technology Can Count Damaged DNA Fragments
Korea Research Institute of Standards and Science (KRISS) unveiled an ultrasensitive competitive immunoassay that quantifies small excised damaged DNA (sedDNA) fragments down to a few thousand molecules, delivering up to 22‑times higher detection than conventional methods. The platform directly measures...
Study Identifies fPRDM16 as Target for Age-Related Pulmonary Fibrosis
A recent study in Current Molecular Pharmacology identifies the transcriptional regulator fPRDM16 as a pivotal factor in age‑related pulmonary fibrosis. The researchers showed that aging diminishes collagen‑I phagocytosis in lung fibroblasts, driven by lysosomal alkalinization and heightened mitochondrial ROS. Restoring...